<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870206</url>
  </required_header>
  <id_info>
    <org_study_id>Birmex-ECA-01-2013</org_study_id>
    <nct_id>NCT01870206</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns</brief_title>
  <official_title>Phase III Immunogenicity, Safety, Poliovirus Excretion and Acceptance of Vaccination OPV (Vero Cells) in Newborns Mexicans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polio is a highly infectious disease caused by a virus. It invades the nervous system, and
      can cause total paralysis in a matter of hours. The virus enters the body through the mouth
      and multiplies in the intestine. Initial symptoms are fever, fatigue, headache, vomiting,
      stiffness in the neck and pain in the limbs. One in 200 infections leads to irreversible
      paralysis (usually in the legs). Among those paralysed, 5% to 10% die when their breathing
      muscles become immobilized. There is no cure for polio, it can only be prevented. Polio
      vaccine, given multiple times, can protect a child for life.

      Compare in newborns the immunogenicity and safety of the vaccine OPV produced by Birmex
      compared with the vaccine OPV produced by Sanofi Pasteur, both produced in Vero cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized clinical trial, which includes 320 newborns of both sexes and residents
      of the state of México, 160 newborns receive the vaccine OPV Birmex and 160 newborns receive
      the vaccine OPV Sanofi Pasteur
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change seroconversion after one dose of trivalent vaccine OPV</measure>
    <time_frame>after the first dose is taken blood samples (baseline, 30 and 60 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the adverse events in newborns babies</measure>
    <time_frame>inmediately after treatment and during 60 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Poliovirus Excretion</measure>
    <time_frame>Evaluate viral excretion rate, basal 7, 14, 21 and 28 days after vaccination of two vaccines against polio OPV in newborns Mexicans</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Trivalent OPV Birmex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newborns receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine. A second dose four weeks after the first application.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trivalent OPV Sanofi Pasteur</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine. A second dose four weeks after the first application.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent OPV Birmex</intervention_name>
    <description>Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.</description>
    <arm_group_label>Trivalent OPV Birmex</arm_group_label>
    <other_name>tOPV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent OPV Sanofi Pasteur</intervention_name>
    <description>Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.</description>
    <arm_group_label>Trivalent OPV Sanofi Pasteur</arm_group_label>
    <other_name>tOPV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newborns babies

          -  Weight ≥ 2.5 kg

          -  Have not received any doses of Polio Vaccine

          -  Whose parents or guardians reside in the work area

          -  Whose parent or guardian accept to sign written informed consent (by the other, father
             or guardian).

        Exclusion Criteria:

          -  Born of a high-risk pregnancy.

          -  Weight ≤ 2.5 kg

          -  Presence of fever, diarrhea, known immunosuppression, respiratory infections.

          -  Treatment with immunosuppressants.

          -  Having neurological diseases.

          -  Require or received surgery in oropharynx.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Rodríguez Álvarez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratorios de Biológicos y Reactivos de México S.A de C.V</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alvaro García-Pérez, MD</last_name>
    <phone>5554222840</phone>
    <phone_ext>139</phone_ext>
    <email>agarciap@birmex.gob.mx</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General de Chalco Dr. Fernando Quiroz Gutierrez</name>
      <address>
        <city>Valle de Chalco</city>
        <state>Estado de México</state>
        <zip>56613</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Monserrat Ávila-Flores, Pediatrics</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.birmex.gob.mx</url>
    <description>Laboratorios de Biológicos y Reactivos de México S.A de C.V</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>September 27, 2013</last_update_submitted>
  <last_update_submitted_qc>September 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Newborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

